Alcohol septal ablation or mavacamten for obstructive hypertrophic cardiomyopathy
- Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by an increased left ventricular wall thickness in the absence of increased afterload conditions. In addition to diastolic dysfunction, obstruction of the left ventricular outflow tract is common in HCM and has an important influence on symptoms and outcome. Over the last five decades or two decades, respectively, surgical myectomy and alcohol septal ablation were the only therapeutic options if standard medical care was not sufficient. Recently, a new option has become available that has the potential to revolutionize the therapeutic strategies for patients with HCM. Mavacamten is a myosin inhibitor that belongs to a completely new drug class and targets the excessive actin–myosin cross-bridging that is the underlying pathology of HCM. By reducing the actin–myosin interactions, mavacamten not only reduces the left ventricular outflow tract (LVOT) obstruction but also seems to have positive effects on the diastolic function, microcirculation, and cardiac structure. This article summarizes the current evidence on alcohol septal ablation and reviews the preclinical and clinical data on mavacamten for the treatment of patients with obstructive HCM.
Author: | Smita ScholtzGND, Volker RudolphORCiDGND, Jan-Christian ReilORCiDGND |
---|---|
URN: | urn:nbn:de:hbz:294-110954 |
DOI: | https://doi.org/10.3390/jcm12206628 |
Parent Title (English): | Journal of clinical medicine |
Publisher: | MDPI |
Place of publication: | Basel |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2024/03/20 |
Date of first Publication: | 2023/10/19 |
Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
Tag: | Open Access Fonds alcohol septal ablation; hypertrophic cardiomyopathy; left ventricular outflow tract obstruction; mavacamten; myosin inhibitor; septal reduction therapy |
Volume: | 12 |
Issue: | 20, Artikel 6628 |
First Page: | 6628-1 |
Last Page: | 6628-17 |
Note: | Article Processing Charge funded by the Deutsche Forschungsgemeinschaft (DFG) and the Open Access Publication Fund of Ruhr-Universität Bochum. |
Institutes/Facilities: | Herz- und Diabeteszentrum NRW, Klinik für Allgemeine und Interventionelle Kardiologie / Angiologie |
Dewey Decimal Classification: | Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit |
open_access (DINI-Set): | open_access |
Licence (English): | Creative Commons - CC BY 4.0 - Attribution 4.0 International |